Staged hepatectomy after emergency transcatheter arterial embolization for ruptured hepatocellular carcinoma. 1998

R Shimada, and H Imamura, and M Makuuchi, and J Soeda, and A Kobayashi, and T Noike, and S Miyagawa, and S Kawasaki
First Department of Surgery, Shinshu University School of Medicine Matsumoto, Japan.

BACKGROUND Staged hepatectomy after emergency transcatheter arterial embolization (TAE) has been advocated in ruptured hepatocellular carcinoma (HCC). However, there have been no reports of clinical series of this strategy. The purpose of this study was to evaluate the protocol of this therapeutic strategy. METHODS Sixteen patients with suspected rupture of HCC were included in the study. After emergency TAE, tumor resectability was assessed, followed by staged hepatectomy or repeated TAE. The patients were reevaluated with regard to rupture of HCCs. RESULTS Primary hemostasis was achieved successfully in all patients. Eleven patients were finally judged to have experienced HCC rupture. Seven of them underwent staged hepatectomy; the other four underwent repeated TAE because their tumors were considered unresectable. Survival time tended to be longer, but not to a significant extent, in patients who underwent hepatectomy (range, 139 to 1527 days; median, 375 days) than in those treated by TAE alone (range, 43 to 1317 days; median, 158 days). CONCLUSIONS Staged hepatectomy after TAE is a rational treatment for patients with ruptured HCC. Although TAE is highly effective for initial hemostasis, hepatectomy appears to provide better long-term survival.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006498 Hepatectomy Excision of all or part of the liver. (Dorland, 28th ed) Hepatectomies
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

R Shimada, and H Imamura, and M Makuuchi, and J Soeda, and A Kobayashi, and T Noike, and S Miyagawa, and S Kawasaki
January 2002, Hepato-gastroenterology,
R Shimada, and H Imamura, and M Makuuchi, and J Soeda, and A Kobayashi, and T Noike, and S Miyagawa, and S Kawasaki
May 1985, Nihon Geka Gakkai zasshi,
R Shimada, and H Imamura, and M Makuuchi, and J Soeda, and A Kobayashi, and T Noike, and S Miyagawa, and S Kawasaki
November 2020, Japanese journal of radiology,
R Shimada, and H Imamura, and M Makuuchi, and J Soeda, and A Kobayashi, and T Noike, and S Miyagawa, and S Kawasaki
September 1989, AJR. American journal of roentgenology,
R Shimada, and H Imamura, and M Makuuchi, and J Soeda, and A Kobayashi, and T Noike, and S Miyagawa, and S Kawasaki
January 2010, Hepato-gastroenterology,
R Shimada, and H Imamura, and M Makuuchi, and J Soeda, and A Kobayashi, and T Noike, and S Miyagawa, and S Kawasaki
January 2018, In vivo (Athens, Greece),
R Shimada, and H Imamura, and M Makuuchi, and J Soeda, and A Kobayashi, and T Noike, and S Miyagawa, and S Kawasaki
May 1988, Rinsho hoshasen. Clinical radiography,
R Shimada, and H Imamura, and M Makuuchi, and J Soeda, and A Kobayashi, and T Noike, and S Miyagawa, and S Kawasaki
September 1986, Rinsho hoshasen. Clinical radiography,
R Shimada, and H Imamura, and M Makuuchi, and J Soeda, and A Kobayashi, and T Noike, and S Miyagawa, and S Kawasaki
September 1992, Nihon Geka Gakkai zasshi,
R Shimada, and H Imamura, and M Makuuchi, and J Soeda, and A Kobayashi, and T Noike, and S Miyagawa, and S Kawasaki
July 1985, Gastroenterology,
Copied contents to your clipboard!